Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab and Tuvonralimab + OH2 for Perioperative Treatment of Stage III Resectable Acral Melanoma
NCT07854522Phase 4Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Oct 2026
- Primary completion
- Sep 2029
01
Overview
A Phase 4 trial of iparomlimab + tuvonralimab, OH2 in acral lentiginous melanoma (ALM), sponsored by Peking University Cancer Hospital & Institute. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
iparomlimab + tuvonralimabOH2
03
Conditions
acral lentiginous melanoma (ALM)
Beyond the preview
Go deeper on NCT07854522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07854522.